Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07542145 · ClinicalTrials.gov registry record · Phase 1
MDMA Assisted Therapy for BN
A Phase 1 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT07542145 is a Phase 1 study that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 40 participants.
The verdict
NCT07542145, a Phase 1 study, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This project will evaluate MDMA Assisted Therapy (MDMA-AT) assisted psychotherapy for the treatment of Bulimia Nervosa (BN) over a 10-week period. Preliminary data suggests that MDMA can facilitate heightened openness and reduce anxiety. This study will determine whether MDMA-assisted therapy can serve as a new treatment for BN. Participants are assigned to one of three groups: MDMA-AT, MDMA-AT-BN, and Standard Treatment (ST). MDMA groups include three experimental session that include dosing, which are each followed by three integrative sessions and also include 12 psychotherapy sessions. A follow-up will take place at 6-months post baseline.
Interventions
- DRUG MDMA-AT
- DRUG MDMA-AT-BN
- BEHAVIORAL Standard Treatment (ST)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-05-22 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07542145
The ClinicalTrials.gov registry entry for NCT07542145 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which MDMA-AT is the first listed.
NCT07542145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07542145 about?
NCT07542145 is a clinical study titled "MDMA Assisted Therapy for BN". This project will evaluate MDMA Assisted Therapy (MDMA-AT) assisted psychotherapy for the treatment of Bulimia Nervosa (BN) over a 10-week period. Preliminary data suggests that MDMA can facilitate heightened openness and reduce anxiety. This study will determine whether MDMA-assisted therapy can se...
What is the current status of trial NCT07542145?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2026-05-22. Estimated completion is 2028-04-30.
What interventions are being tested in trial NCT07542145?
The interventions under investigation include: MDMA-AT (DRUG), MDMA-AT-BN (DRUG), Standard Treatment (ST) (BEHAVIORAL).
Who is sponsoring clinical trial NCT07542145?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.